Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab long-term safety in bone metastases
NCT00950911Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2009
- Primary completion
- Feb 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of denosumab in bone metastases, sponsored by Amgen. Started Jul 2009; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00950911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950911.